Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
15 studies found for:    "methodist hospital" | Open Studies | "Gastrointestinal Diseases" | United States, Texas | Houston
Show Display Options
Rank Status Study
1 Recruiting Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Condition: Colorectal Cancer
Interventions: Drug: celecoxib;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Other: placebo
2 Not yet recruiting TAA-SPECIFIC CTLS FOR SOLID TUMORS (TACTASOM)
Conditions: Bladder Cancer;   Breast Cancer;   Colorectal Cancer;   Endometrial Cancer;   Gastric Cancer;   Glioma/Medulloblastoma;   Head and Neck Cancer;   HCC;   Lung Cancer;   Melanoma;   Neuroblastoma;   Sarcoma (Osteo-, Synovial, Rhabdomyo-, Etc);   Pancreatic Cancer;   Prostate Cancer;   Renal Cell Carcinoma;   Thyroid Cancer
Intervention: Biological: TAA-Specific CTLs
3 Recruiting S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer;   Gastric Cancer
Interventions: Drug: FOLFOX regimen;   Drug: docetaxel;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin
4 Recruiting Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Adult Hepatocellular Carcinoma;   Advanced Adult Hepatocellular Carcinoma;   BCLC Stage C Adult Hepatocellular Carcinoma;   BCLC Stage D Adult Hepatocellular Carcinoma;   Localized Non-Resectable Adult Liver Carcinoma;   Recurrent Adult Liver Carcinoma
Interventions: Drug: Doxorubicin Hydrochloride;   Drug: Sorafenib Tosylate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
5 Recruiting Diet and Physical Activity Change or Usual Care in Improving Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Behavioral: behavioral dietary intervention;   Behavioral: exercise intervention;   Other: counseling intervention;   Other: educational intervention;   Behavioral: compliance monitoring;   Other: questionnaire administration;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
6 Recruiting Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
Condition: Colorectal Cancer
Interventions: Drug: FOLFOX (chemotherapy);   Other: 5 FUCMT (chemoradiation);   Procedure: surgery;   Procedure: magnetic resonance imaging or endorectal ultrasound
7 Recruiting Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: elesclomol sodium;   Drug: paclitaxel
8 Recruiting Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Adenocarcinoma;   Stage IB Esophageal Cancer;   Stage IIA Esophageal Cancer;   Stage IIB Esophageal Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIB Esophageal Cancer
Interventions: Radiation: Radiation Therapy;   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Trastuzumab;   Procedure: Therapeutic Conventional Surgery;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
9 Recruiting Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Conditions: Lung Carcinoid Tumor;   Metastatic Gastrointestinal Neuroendocrine Tumor G1;   Recurrent Gastrointestinal Neuroendocrine Tumor G1;   Recurrent Merkel Cell Carcinoma;   Regional Gastrointestinal Neuroendocrine Tumor G1;   Stage III Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma;   Thyroid Gland Medullary Carcinoma
Interventions: Drug: Pazopanib Hydrochloride;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
10 Recruiting Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery
Conditions: Pancreatic Acinar Cell Carcinoma;   Pancreatic Ductal Adenocarcinoma;   Pancreatic Intraductal Papillary-Mucinous Neoplasm;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
Interventions: Drug: Gemcitabine Hydrochloride;   Drug: Erlotinib Hydrochloride;   Radiation: 3-Dimensional Conformal Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Capecitabine;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
11 Recruiting S0820, Adenoma and Second Primary Prevention Trial
Condition: Colorectal Neoplasms
Interventions: Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac
12 Recruiting The Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy
Condition: Hepatic Encephalopathy
Interventions: Drug: Placebo;   Drug: Rifaximin
13 Recruiting Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
Conditions: Hepatoblastoma;   Stage I Childhood Hepatocellular Carcinoma;   Stage II Childhood Hepatocellular Carcinoma;   Stage III Childhood Hepatocellular Carcinoma;   Stage IV Childhood Hepatocellular Carcinoma
Interventions: Procedure: Therapeutic Conventional Surgery;   Drug: Cisplatin;   Drug: Fluorouracil;   Drug: Vincristine Sulfate;   Drug: Doxorubicin Hydrochloride;   Drug: Irinotecan Hydrochloride;   Drug: Temsirolimus;   Procedure: Liver Transplantation;   Other: Laboratory Biomarker Analysis
14 Recruiting Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Localized Resectable Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: sorafenib tosylate;   Other: placebo;   Other: laboratory biomarker analysis
15 Recruiting Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Conditions: Adult Cholangiocarcinoma;   Advanced Adult Hepatocellular Carcinoma;   BCLC Stage C Adult Hepatocellular Carcinoma;   BCLC Stage D Adult Hepatocellular Carcinoma;   Hilar Cholangiocarcinoma;   Localized Non-Resectable Adult Liver Carcinoma;   Recurrent Adult Liver Carcinoma;   Recurrent Childhood Liver Cancer;   Recurrent Extrahepatic Bile Duct Carcinoma;   Recurrent Gallbladder Carcinoma;   Stage II Gallbladder Cancer;   Stage III Childhood Hepatocellular Carcinoma;   Stage IIIA Gallbladder Cancer;   Stage IIIB Gallbladder Cancer;   Stage IV Childhood Hepatocellular Carcinoma;   Stage IV Distal Bile Duct Cancer;   Stage IVA Gallbladder Cancer;   Stage IVB Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Carcinoma
Interventions: Drug: Trametinib;   Drug: Leucovorin Calcium;   Drug: Fluorouracil;   Drug: Capecitabine;   Other: Laboratory Biomarker Analysis

Indicates status has not been verified in more than two years